Donghui Liu

Department of Cardiology, Fujian Provincial Hospital, Fujian Provincial Key Laboratory of Cardiovascular Disease, Fujian Cardiovascular Institute, Provincial Clinical Medicine College of Fujian Medical University, Fuzhou, China

\*Address all correspondence to: liudonghuis@126.com

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**29**

fj.12-212753

*High-Density Lipoprotein: From Biological Functions to Clinical Perspectives*

[8] Rye KA, Barter PJ. Cardioprotective functions of HDLs. Journal of Lipid Research. 2014;**55**:168-179. DOI:

[10] Miller GJ, Miller NE. Plasma-highdensity-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1975;**1**:16-19. DOI: 10.1016/

[11] Khera AV, Demler OV, Adelman SJ. Cholesterol efflux capacity, high-density

lipoprotein particle number, and incident cardiovascular events: An analysis from the JUPITER trial (justification for the use of statins in prevention: An intervention trial evaluating rosuvastatin). Circulation. 2017;**135**:2494-2504. DOI: 10.1161/ CIRCULATIONAHA.116.025678

[12] Brooks-Wilson A, Marcil M, Clee SM. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nature Genetics. 1999;**22**:336-345. DOI: 10.1038/11905

[13] Tall AR, Yvan-Charvet L,

10.1016/j.cmet.2008.03.001

[14] Lee JY, Parks JS. ATP-binding cassette transporter AI and its role in HDL formation. Current Opinion in Lipidology. 2005;**16**:19-25. DOI: 10.1097/00041433-200502000-00005

[15] Tang C, Liu Y, Kessler PS. The macrophage cholesterol exporter ABCA1 functions as an anti-

inflammatory receptor. The Journal of

Terasaka N. HDL, ABC transporters, and cholesterol efflux: Implications for the treatment of atherosclerosis. Cell Metabolism. 2008;**7**:365-375. DOI:

[9] Rosenson RS, Brewer HB Jr, Ansell BJ. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nature Reviews. Cardiology. 2016;**13**:48- 60. DOI: 10.1038/nrcardio.2015.124

10.1194/jlr.R039297

s0140-6736(75)92376-4

*DOI: http://dx.doi.org/10.5772/intechopen.91136*

Hjortland MC. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. The American Journal of Medicine. 1977;**62**:707-714. DOI: 10.1016/0002-9343(77)90874-9

[2] Gotto AM, Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: A working group report and update. Journal of the American College of Cardiology. 2004;**43**:717-724.

DOI: 10.1016/j.jacc.2003.08.061

[3] Gordon DJ, Probstfield JL,

10.1161/01.cir.79.1.8

NEJMoa0706628

[5] Ballantyne CM, Miller M, Niesor EJ. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: Results of a phase IIb dose-ranging study. American Heart Journal. 2012;**163**: 515-521. DOI: 10.1016/j.ahj.2011.11.017

[6] Joy TR. Novel HDL-based

[7] van der Vorst EP, Vanags LZ, Dunn LL. High-density lipoproteins suppress chemokine expression and proliferation in human vascular smooth muscle cells. FASEB Journal. 2013;**27**:1413-1425. DOI: 10.1096/

therapeutic agents. Pharmacology & Therapeutics. 2012;**135**:18-30. DOI: 10.1016/j.pharmthera.2012.03.004

Garrison RJ. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;**79**:8-15. DOI:

[4] Barter PJ, Caulfield M, Eriksson M. Effects of torcetrapib in patients at high risk for coronary events. The New England Journal of Medicine. 2007;**357**:2109-2122. DOI: 10.1056/

**References**

[1] Gordon T, Castelli WP,

*High-Density Lipoprotein: From Biological Functions to Clinical Perspectives DOI: http://dx.doi.org/10.5772/intechopen.91136*
